fda compounding semaglutide crackdown 2025 news The growing availability of compounded GLP-1 weight-loss drugs has prompted warnings from doctors and the U.S. Food and Drug Administration. Link in comments⬇️ FDA is cracking down on

The Protein Problem This is the other side of the equation and it hits women over 40 especially hard

The magnitude of metabolic adaptation typically correlates with the speed and extent of weight loss

If you are looking to expand your practices offerings, review our comprehensive guide comparing the top Botox training programs to find the right certification pathway for your clinic

All authors have reviewed the submitted version and agreed to publish the manuscript

Originally developed to manage type 2 diabetes, GLP-1 receptor agonists have gained popularity for their appetite-suppressing and weight-loss effects, with the study finding that most prescriptions are now issued to women without diabetes

A heads up on the evidence